Analystreport

Royalty Pharma (NASDAQ:RPRX) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations